Medicortex Finland Plc appointing a new advisor

Medicortex is an innovative clinical stage biotechnology company focusing on development of diagnostics and therapy for brain injuries. Company’s short-term focus is to complete development of a rapid urine test, company’s lead product ProbTBI^TM kit for detection of biomarkers of mild traumatic brain injury, followed by prototype production and clinical evaluation. Professor Hannula will be part of the team to move the company forward to bring its breakthrough products to the clinics to address a significant unmet medical need.

Professor Hannula has a Doctor of Science degree from the Tampere University of Technology and his current position is Vice-Rector for partnerships and strategic engagement at the University of Turku, Finland. He has led the substantial extension of research and education at the University of Turku to technical sciences and headed the establishment of a new faculty of technology. Professor Hannula is an experienced leader and he has extensive experience in different academic leadership positions. Additionally, he serves as a board member or chair for several organizations inside and outside the academia, including private owned companies, public organizations and national defense.

“Medicortex is honored to have one of the most renowned and successful leaders in academia and strategic management to join the Medicortex team in this advisory position. We believe that we have assembled the top multidisciplinary advisory team", says Dr. Adrian Harel, CEO of Medicortex. “The broad potential of our TBI technology pipeline combined with the supplemented outstanding team of experts marks a major step forward in advancing Medicortex to the leading technology company in the field of noninvasive testing of head injury and beyond”, Dr. Harel adds. 

“I am happy to join the Advisory Board of Medicortex”, Professor Hannula says. “I’m honored to be part of the team to advise the company at its extremely interesting stage to successfully move forward to get its products on the market. Brain injuries affect a large patient population and we have an outstanding opportunity to make major contributions towards finding an affordable test and reasonable treatment for patients with this condition”, Professor Hannula concludes.

Facts about Professor Mika Hannula

Name: Mika Hannula
Born: 1968
Current position: Vice-rector for partnerships and strategic engagement, University of Turku, Finland

Previous positions
- Director (part time), Technology Campus Turku
- President, Tampere University of Technology, Finland
- Professor at both University of Turku, and Tampere University of Technology

Other academic positions
- Chairman, advisory board of National Defense University, Finland
- Adjunct professor, National Defense University
- Adjunct professor, Tampere University

Education
- Doctor of Science (Tech), 1999
- Licentiate of Technology, 1998
- Master of Science (Tech) in Industrial Engineering and Management with distinction, 1993

Military rank: Lieutenant Colonel (in reserve)

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the results, operations, achievements and performance specifically or indirectly indicated in such forward-looking statements. Such risks, uncertainties and other important factors include, among other things, risks related to the implementation of the company’s strategy and availability of financing, general economic and market situation and other risks. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.